Frankfurt
30.12.25 | 09:11
0,193 Euro
-1,53 % -0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,201 | 0,206 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12.25 | IMPLANET Announces First Surgeries Using the JAZZ System in China | 236 | Business Wire | Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced... ► Artikel lesen | |
| 13.11.25 | Implanet partners with 8i Robotics for multi-arm surgical robot | 2 | Investing.com | ||
| 13.11.25 | IMPLANET signs partnership agreement with 8i Robotics Inc. for the clinical evaluation of a surgeon-supervised robotic system for spine surgery | 459 | Business Wire | Clinical evaluation of the world's first multi-arm surgical robot Strategic partnership aiming for medium-term market launch of an innovative robotic solution in Europe and adapted to... ► Artikel lesen | |
| IMPLANET Aktie jetzt für 0€ handeln | |||||
| 14.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.10.2025 | 313 | Xetra Newsboard | Das Instrument 1J8N CH0350494719 BQUE CANT.D.GEN.NAM.SF 50 EQUITY wird cum Kapitalmassnahme gehandelt am 14.10.2025 und ex Kapitalmassnahme am 15.10.2025 The instrument 1J8N CH0350494719 BQUE CANT.D.GEN.NAM.SF... ► Artikel lesen | |
| 07.10.25 | Implanet S.A. reports Q3 results | 6 | Seeking Alpha | ||
| 07.10.25 | IMPLANET Reports Q3 2025 Revenue of €2.9 Million, Up +26% | 342 | Business Wire | Nine-month 2025 revenue of €8.7 million, up +36% compared to the same period last year
U.S. activity up +22% in Q3 2025 and multiplied by 1.8x over the first nine months of 2025 (vs. 2024)... ► Artikel lesen | |
| 23.09.25 | IMPLANET Signs Exclusive Distribution Agreement with TINAVI Medical Technologies for the TiRobot Spine Surgery System | 422 | Business Wire | Strengthening the commercialization strategy for cobotic1 solutions in orthopedic surgery
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology... ► Artikel lesen | |
| 16.09.25 | IMPLANET Announces First-Half 2025 Results | 371 | Business Wire | First-half revenue up 41% to €5.8 million
16% improvement in net result from continuing operations
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME)... ► Artikel lesen | |
| 15.07.25 | IMPLANET Announces CFDA Approval for Its Innovative JAZZ Range in China | 413 | Business Wire | Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, PEA-PME eligible), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced... ► Artikel lesen | |
| 08.07.25 | IMPLANET Announces Half-Year Revenue for 2025 up 41% to €5.8 Million | 1.026 | Business Wire | Second quarter 2025 up +71% to €3.2 millions
Revenue in the United States increased by a factor of 5.4 in Q2 2025 and by 1.7x for the first half of 2025 compared to 2024
Strong first... ► Artikel lesen | |
| 24.04.25 | IMPLANET to Co-Exhibit its Innovative Spine Solutions Alongside 8i Robotics' Next-Gen Robotic Solutions at AANS in Boston | 401 | Business Wire | Spine tech innovator IMPLANET will demo and display its game-changing portfolio in tandem with 8i Robotics' robot systems at Booth #1029, April 25-28, 2025
Regulatory News:
At this year's American... ► Artikel lesen | |
| 14.04.25 | Minutes of IMPLANET's Annual General Meeting Held on April 11, 2025 | 572 | Business Wire | Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, éligible PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced... ► Artikel lesen | |
| 09.04.25 | IMPLANET Reports Revenue of €2.58 Million in Q1 2025, Up +16% | 408 | Business Wire | +16% revenue growth compared to Q1 2024
Performance driven by strong export growth outside France and the United States (+42% vs. Q1 2024)
Regulatory News:
IMPLANET (Euronext Growth:... ► Artikel lesen | |
| 04.03.25 | IMPLANET Reports Its 2024 Full-Year Results | 656 | Business Wire | 2024 full-year revenue up +26% compared to fiscal year 2023
Continued strict control of operational costs throughout the period
Regulatory News:
IMPLANET (Euronext Growth: ALIMP,... ► Artikel lesen | |
| 14.01.25 | IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million | 521 | Business Wire | Continued acceleration in quarterly revenue growth since Q2 2024, with Q4 2024 reaching nearly €3.0 million, up 81% versus 2023
Strong full-year performance in the medical equipment distribution... ► Artikel lesen | |
| 06.01.25 | IMPLANET Announces Its 2025 Financial Calendar | 615 | Business Wire | Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 48,980 | +0,60 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,920 | +0,54 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| DRAEGERWERK | 69,40 | +0,14 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener Aktien - Abschlussmeldung | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener... ► Artikel lesen | |
| GERRESHEIMER | 27,580 | 0,00 % | Comeback 2026! Verzehnfachung möglich? Evotec, Gerresheimer, Desert Gold Aktie! | Auf der Suche nach einem möglichen Verzehnfacher im Gold-Sektor? Dies halten Analysten bei Desert Gold für möglich. Die jüngste PEA für das Flaggschiff-Gold-Projekt löst neue Kursfantasie aus. Damit... ► Artikel lesen | |
| INTUITIVE SURGICAL | 486,45 | -0,55 % | Where Will Intuitive Surgical Be in 5 Years? | ||
| BICO GROUP | 1,925 | -0,93 % | BICO Group AB: Jesper Hagberg appointed as Chief Operations & Digital Officer for BICO Group AB | BICO Group AB today announces the appointment of Jesper Hagberg as Chief Operations & Digital Officer.
Jesper Hagberg brings over 25 years of experience as CIO, CDO and Transformation Leader, driving... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,080 | +1,27 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,018 | -5,38 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
| HEALWELL AI | 0,548 | +3,30 % | HEALWELL AI: HEALWELL AI Provides Additional Information Regarding November 3, 2025, Release Where it Announced Strategic Divestments | Toronto, Ontario--(Newsfile Corp. - December 31, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| OTTOBOCK | 65,25 | 0,00 % | IPO-Rückblick 2025: TKMS, Klarna, Ottobock und Circle im Anleger-Check | Guten Tag, liebe Leserinnen und Leser,
2025 war ein vergleichsweise starkes Jahr für Neuemissionen. Allein in der ersten Jahreshälfte wagten weltweit 539 Unternehmen den Schritt an die Börse und sammelten... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,537 | -0,74 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval
SEATTLE... ► Artikel lesen | |
| PING AN HEALTHCARE | 1,542 | -1,66 % | PA GOODDOCTOR (01833): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | ||
| NETRAMARK | 0,675 | -0,74 % | NetraMark blickt auf ein transformatives Quartal mit wichtigen Erfolgen zurück | Anstieg des Auftragsbestands auf 2,5 Mio. CAD, Abschluss der CPIM-Gespräche mit der FDA, Annahme der Studie zur Veröffentlichung im Verlagsportfolio
von Nature, Onboarding eines wichtigen Vertriebspartners... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,190 | -0,52 % | Co-Diagnostics Announces Reverse Stock Split | SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented... ► Artikel lesen | |
| INSULET | 242,30 | -0,78 % | Insulet: FDA Approves Enhancements To Omnipod 5 Algorithm | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. The new 100... ► Artikel lesen |
IMPLANET SA gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,193 Euro und damit -1,53 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPLANET SA finden Sie auf Wallstreet Online.